Medically supervised resistance training and adequate protein intake may help minimize the loss of lean body mass in people taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for weight loss, new data suggest.
The findings came from a prospective 6-month study of 200 adults with overweight or obesity who received education on resistance training and protein intake at the time of initiating semaglutide or the dual GLP-1/glucagon-insulinotropic peptide tirzepatide. At 6 months, bioelectrical impedance assessment showed they had lost approximately 13% of their body weight but only about 3% of their muscle mass.
“This reinforces the importance of these medications being used under the care of experienced providers who can offer guidance on physical activity, nutrition, and body composition. When used correctly,…